



Xellia Pharmaceuticals demonstrates commitment to the fight against sepsis by providing support for Sepsis Awareness Month

Copenhagen, Denmark, 29 September 2020 - Xellia Pharmaceuticals ('Xellia'), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, announces support for Sepsis Awareness Month.

Sepsis is the third leading cause of death after heart disease and cancer in the USⁱ, affecting more than 1.7 million peopleⁱⁱ and killing more than 270,000 people within a single yearⁱⁱⁱ.

September has been designated as [Sepsis Awareness Month](#) by the Sepsis Alliance since 2011, with individuals, healthcare professionals, businesses and organizations from all areas of medicine, invited to help raise awareness each year.

In 2019, Xellia Chicago participated in a Sepsis 5k run to increase awareness around the disease. As a result of the COVID-19 crisis in 2020, the annual event cannot be held in person this year, therefore, Xellia Chicago instead led a company-wide Sepsis Virtual Run Challenge. On a global scale, on 26 September 2020, Xellia employees across 5 countries walked and ran 5 km distances to increase awareness.

Craig Boyd, President, Xellia North America, commented: *"One in five deaths worldwide are due to sepsis, and it is the leading cause of death in US hospitals^{iv}. At Xellia, we are proud to manufacture and produce key anti-infectives, to combat sepsis, and we understand the importance of delivering a consistent and reliable supply.*

"On behalf of the Xellia team, I'd like to thank every employee around the globe for joining Xellia Chicago in our Sepsis Virtual Run Challenge, and the provided support."

- Ends -

For more information, please contact:

Xellia Pharmaceuticals
Carl-Åke Carlsson, CEO
Tel: +45 32 64 55 00

Instinctif Partners (International media relations)
Melanie Toyne-Sewell / Siobhan Sanford
Tel: +44 (0) 7890 022 814 / +44 (0) 7534 247 411
Email: xellia@instinctif.com

Notes to Editors

About Xellia Pharmaceuticals

Xellia Pharmaceuticals (“Xellia”) is a specialty pharmaceutical company developing, manufacturing and commercializing anti-infective treatments against serious and often life-threatening bacterial and fungal infections.

With over 115 years of experience, Xellia is a world-leading trusted supplier of several important established anti-infective drugs, comprising active pharmaceutical ingredients as well as injectable products. Continuing the Company’s evolution, Xellia is generating an innovative pipeline of value-added anti-infective medicines intended to enhance patient care, providing convenience and ease of use for healthcare professionals.

Headquartered in Copenhagen, Denmark, Xellia has a global footprint with R&D, manufacturing and commercial operations across Europe, Asia, the Middle East and North America and is investing significantly to expand its sales and manufacturing capabilities within the United States. Xellia is wholly owned by Novo Holdings A/S and employs a dedicated team of over 1,800 people.

Further information about Xellia can be found at: www.xellia.com. Connect with us on [LinkedIn](#).

ⁱ JAMA. 2014;312(1):90-92. 2. Rhee C, Dantes R, Epstein L, et al. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014. JAMA. 2017;318(13):1241-1249.

ⁱⁱ Rhee C, Dantes R, Epstein L, et al. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014. JAMA. 2017;318(13):1241-1249

ⁱⁱⁱ Centers for Disease Control and Prevention. Leading causes of death.

<https://www.cdc.gov/nchs/fastats/leading-causes-of-death.html>. Accessed August 27, 2020

^{iv} Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200–211.